

WEBINAR

NURHT CAUCUS



DATE  
25 SEP

TIME  
10:00 AM ET

# Male Contraception: Where We Stand and What's Ahead

The Quest for a More Equitable  
Contraception for All

WITH



CTIExchange



# NURHT Caucus' Co-Chairs

Julie Heinsen

Program  
Officer,  
Injectables  
Access  
Collaborative

[jheinsen@path.  
org](mailto:jheinsen@path.org)



Megan  
Christofield

Project Director,  
Expanding  
Method Choice,  
Jhpiego

[megan.christofiel  
d@jhpiego.org](mailto:megan.christofield@jhpiego.org)



**Emily Hoppes**

**Technical Advisor  
Contraceptive Research,  
Development, and  
Introduction division at  
FHI 360**





New pre-print out today!



# **The Contraceptive Product Pipeline**

Where We Are and What We've Learned



Visit and follow along!



[www.ctiexchange.org/cti-tracker](http://www.ctiexchange.org/cti-tracker)

## CTI Tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

For additional information on contraceptive R&D, visit databases managed by our partners:

CITDBase

Non-Hormonal Reversible Male Contraception Database

MPT Development Database

Search

Show Filters

User

Hormonal/Non-Hormonal

Delivery Type

Intended Duration

Development Stage

MPT or Non-MPT

Mechanism of Action

Apply Filters

Reset Filters

All (218) Active (123) Inactive (95)

Last Updated - Descending

ACTIVE

Last updated: AUGUST 6, 2025

### 6 Month Injectable Contraceptive

USER: Female | HORMONAL: Hormonal | DELIVERY TYPE: Injectable | INTENDED DURATION: Short-Acting  
DEVELOPMENT STAGE: Phase III | DEVELOPER(S)/RESEARCHER(S): FHI 360

ACTIVE

Last updated: JULY 31, 2025

### Centchroman


USER: Female | HORMONAL: Non-Hormonal | DELIVERY TYPE: Oral | INTENDED DURATION: Short-Acting  
DEVELOPMENT STAGE: Single-Country Approval  
DEVELOPER(S)/RESEARCHER(S): King George's Medical University, India Health Action Trust, Central Drug Research Institute, India, HLL Lifecare Limited

ACTIVE


Last updated: JULY 30, 2025

### Peptide LL-37


# There are 123 active products in the pipeline.



\*Note: 5 products do not fall neatly within these categories




# There are 123 active products in the pipeline.




In 2018, the split between hormonal vs. nonhormonal male methods being developed was 50/50.

Development Stage



- Discovery and Early Development
- Pre-Clinical
- Clinical
- Single Country Approval

# Overview of the male product pipeline





# Hormonal male methods reaching clinical development

Non-hormonal				
Discovery & Early Development				
Pre-Clinical Development				
Clinical Development				
Single Country Approval				
PRODUCT	PHASE	PAST & PRESENT DEVELOPERS		DELIVERY TYPE
11b-MNTDC / 11 $\beta$ /19/17 $\beta$	Phase I*	BIOQUAL, Inc, NICHD & NIH Contraceptive Development Program Sites, Health Decisions		Injectable <i>or</i> Oral
Dimethandrolone Undecanoate	Phase I**	BIOQUAL, Inc, NICHD, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, NIH Contraceptive Development Program Sites		Injectable <i>or</i> Oral
NES + Testosterone Gel	Phase II	Population Council, Global Clinical Sites, Health Decisions, NICHD, Contraline		Transdermal

\*Product has reached Phase I clinical development but last published in 2020


\*\*Product has reached Phase I clinical development but returned to non-clinical in vitro evaluation as of 2022

# Nonhormonal male methods reaching clinical development

PRODUCT	PHASE	DEVELOPERS	DELIVERY TYPE
ADAM Vas-Occlusive Device	Phase I	Contraline, LLC	Vas Deferens
Plan A Male Contraceptive System	Phase I	NEXT Life Sciences	Vas Deferens
Silodosin	Phase I	TSS Shripad Hegde Kadave Institute of Medical Sciences	Oral
Justicia Gendarussa Extract	Phase II	Airlangga University	Oral
YCT-529 Oral Male Contraceptive	Phase Ia/Ib	YourChoice Therapeutics, University of Minnesota	Oral
Vas Deferens RISUG	Phase III*	Indian Council for Medical Research, Indian Institute of Technology, Kharagpur, University of Rajasthan	Vas Deferens
GELdom Condom	Phase II	Eudaemon, University of Wollongong, Australia	Barrier

\*Product has 40+ year development pathway. Developers have indicated Phase III research pursued, not confirmed

# Progression of Contraceptive Products through Development



# Key Observations & Challenges

---

- **Volatility in Product Development**

- Among inactive products, development stalled during early development for 30%, pre-clinical stage for 28%, and clinical stages for 42%
- 27 products changed developers or teams over the course of the review

- **Shifts in R&D Landscape**

- Decline in large for-profit company involvement
- Rise of smaller reproductive health start-ups

- **Systemic Challenges**

- Chronic underinvestment slows progress
- Scientific and regulatory complexity adds barriers

# Thank you!

**subscribe**



**visit**



[www.ctiexchange.org](http://www.ctiexchange.org)

**connect**







**Heather Vahdat**  
**Executive Director**  
**Male Contraceptive**  
**Initiative (MCI)**


**Logan Nickels, PhD**  
**Chief Research  
Officer**  
**Male Contraceptive  
Initiative (MCI)**



# Reproductive Autonomy for **All.**


Male Contraceptive Initiative  
RHSC NURHT Meeting

Heather Vahdat, MPH  
Logan Nickels, PhD  
25 September 2025



# About Male Contraceptive Initiative

**Male Contraceptive Initiative (MCI)** is a global hub and ecosystem facilitator for the entire **non-hormonal, reversible male contraception** industry.



# MCI's Approach


---

## 1. Funding and Supporting Research and Development

We commit the majority of our funding to activities supporting researchers in their work. These funds support the development of new male methods and provide professional training and mentoring opportunities for scientists.

## 2. Advocating for Male Contraception

MCI supports global-level advocacy activities to ensure that products developed in the space are supported for success beyond the bench. This includes supporting the elucidation of regulatory pathways, market research activities, and working with governments, ministries of health and other key partners to build awareness and financial support for male contraceptive product development.





# There is High Global Demand

## Significant interest in USA / LMICs

All countries have >75% interest in trying a novel male method within 5 years.

Form/product route of administration is the top decision-making criteria in all countries

## High female partner trust


50-86% would trust their partner if told their partner was taking a contraceptive

## Post-Dobbs Supreme Court Decision

Data at right show pre-Dobbs survey results - Post-Dobbs survey show now about half (49%) of men interested within 12 months of availability

## Interest in Novel Male Birth Control Methods

*Time to trial by Men for Male Contraceptive Technologies, Cumulative.*



# Status of Male Contraceptive Development

---

## ***Fundamental And Technical Advances Enable Multiple And Diverse TPPs***


- An early-stage, but emerging pipeline.
- Improved understanding of male reproductive biology has enabled the identification of multiple promising sperm-based contraceptive targets
- Modern computational modeling, drug screening, and medchem allows for faster and more efficient drug R&D efforts
- Clinical advances
  - A recently completed phase 11b study on a male-use hormonal gel (NES/T, Ph 2b) provides a regulatory roadmap and a likely first-in-class product
  - Two biotech companies with non-hormonal male contraceptive programs have advanced to clinical stages and a group of nonclinical programs are in pursuit

# Mechanisms of Male Contraception

## Spermatogenesis

- Stopping new sperm from developing
- Time for onset and return to fertility


*Includes hormonal, non-hormonal, and thermal methods*



## Sperm Transport

- Blocking the exit of sperm
- Possibility of drug-based approaches


*Small field outside of vas-occlusive devices, includes barrier methods*



## Sperm Function

- Directly hampering sperm function
- Male AND / OR female delivery
- Possibility of on-demand contraception

*Innovative, exciting, and difficult sector*



# Contraceptive Products in Development

## Hormonal Contraception

A daily gel rubbed on the shoulders, a daily oral pill, and a longer-term injectable formulation are all in clinical trials.\*\*

## Reversible Vasectomy\*

These medical devices can be effective for years and require an outpatient administration procedure. As medical devices, they can have a shorter time-to-market.

## Non-Hormonal Contraception\*

An exciting research field with hundreds of possible targets. Products can be short-acting, on-demand, long-acting, or even unisex.

\* - Visit <https://www.malecontraceptive.org/the-pipeline.html> to learn more about our focus areas!

\*\* - Visit <https://www.malecontraception.center/> for more information on clinical trials!



# Hormonal Male Contraception



Spermatogenesis

## NES/T

Nestorone® / Testosterone

*Daily transdermal gel,  
rubbed on shoulders*

- Population Council
- Phase IIb, clinical efficacy

**~3-4 years from  
approval**

## Additional hormonal products (early-stage clinical development from Population Council)

- *Daily oral pill: **11 $\beta$ -MNTDC***
- *Daily oral pill & ~3-monthly injectable: **DMAU***





# Reversible, Non-Hormonal Vas-Occlusive Devices



## **ADAM**

*Contraline*

Hydrogel polymer, injected  
into vas deferens

- Early clinical studies

**~3 years to  
approval**


## **Plan A (RISUG)**

*NEXT Life Sciences*

Hydrogel polymer, injected  
into vas deferens

- Pre-clinical US
- Clinical India  
(RISUG)

**~5 years to  
approval**




# Non-Hormonal Once Daily Male Pill - YCT-529

## Spermatogenesis

- Prevents sperm cell development AND mature sperm release

YourChoice Therapeutics  
**YCT-529 : ~5  
years to approval**



## YourChoice Therapeutics **YCT-259**

- Daily oral pill
- Advancing to Phase II clinical studies
- Developed by California based biotech




# Non-Hormonal Wearable Methods - Thermal

## Spermatogenesis

- Causes sperm cell apoptosis
- Mechanism not well understood

Entrelac.coop

**Androswitch:**  
Unclear market  
timeline



## Entrelac.coop Androswitch


- Medical Device
- Largely EU / French setting
- Seeking first approval for clinical studies
- Safety, efficacy, reversibility unproven

# Non-Hormonal On-Demand Pill - Sacyl

## Sperm Function

- Preventing the ability of sperm to “swim”
- Potential unisex contraceptive

Sacyl Pharmaceuticals  
**~7-10 years to approval**



**SACYL** PHARMACEUTICALS



## Sacyl Pharmaceuticals sAC Inhibitor

- On-demand oral pill
- Optimizing timing and potency
- Seeking approval for human studies 2025-2026

# MCI-RHSC Collaborative Opportunities

---

- Continued collaboration with NURHT to keep members apprised of pipeline progress
- Consider potential for joint advocacy efforts through A&AWG
- Facilitate conversations between RHSC manufacturers/other members and MCI grantees (i.e. product innovators) to share information and develop strategies to support parallel introduction of products in LMICs
- Share information regarding local/regional production capacity, regional regulatory harmonization efforts, and product registration processes.
- Shared advocacy to address myths and misperceptions about the demand for male contraceptive methods and to promote their inclusion in the mix of reproductive health supplies



# Reproductive Autonomy for All.

Meaningful relationships  
Stronger families  
Improved health / educational / economic outcomes  
Equity in contraceptive burden and opportunity  
Male engagement in reproduction  
Broad improvement in men's health  
Better sex education  
A new model of healthcare  
Contraception for anyone who wants it

**We can create a better world for everyone.**



THANK YOU!



The image features a light blue background. In the center, there is a large, light beige rectangular shape. Overlapping the left side of this beige shape is a light blue shape that resembles a speech bubble or a stylized letter 'L'. Centered on the beige shape is the text 'Q&A' in a bold, dark blue, sans-serif font.

**Q&A**